| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9, 1-14, 2017 | 3234 | 2017 |
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013 | 2314 | 2013 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1776 | 2017 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1233 | 2017 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 727 | 2014 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 487 | 2016 |
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 408 | 2017 |
| Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ... Journal of Clinical Oncology 35 (23), 2624-2630, 2017 | 393 | 2017 |
| BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ... Cancer discovery 9 (2), 210-219, 2019 | 384 | 2019 |
| A direct characterization of human mutation based on microsatellites JX Sun, A Helgason, G Masson, SS Ebenesersdóttir, H Li, S Mallick, ... Nature Genetics, 2012 | 384 | 2012 |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated … AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ... Gynecologic oncology 147 (2), 267-275, 2017 | 274 | 2017 |
| A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal JX Sun, Y He, E Sanford, M Montesion, GM Frampton, S Vignot, JC Soria, ... PLoS computational biology 14 (2), e1005965, 2018 | 259 | 2018 |
| ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017 | 256 | 2017 |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ... Journal of gastrointestinal oncology 9 (4), 610, 2018 | 250 | 2018 |
| Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ... The oncologist 22 (12), 1478-1490, 2017 | 221 | 2017 |
| Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 JS Ross, M Fakih, SM Ali, JA Elvin, AB Schrock, J Suh, JA Vergilio, ... Cancer 124 (7), 1358-1373, 2018 | 218 | 2018 |
| Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. DR Spigel, AB Schrock, D Fabrizio, GM Frampton, J Sun, J He, K Gowen, ... Journal of Clinical Oncology 34 (15_suppl), 9017-9017, 2016 | 211 | 2016 |
| Genomic profiling of small-bowel adenocarcinoma AB Schrock, CE Devoe, R McWilliams, J Sun, T Aparicio, PJ Stephens, ... JAMA oncology 3 (11), 1546-1553, 2017 | 206 | 2017 |
| A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability–high cases in 67,000 … SE Trabucco, K Gowen, SL Maund, E Sanford, DA Fabrizio, MJ Hall, ... The Journal of Molecular Diagnostics 21 (6), 1053-1066, 2019 | 202 | 2019 |
| Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations JS Ross, K Wang, CE Sheehan, AB Boguniewicz, G Otto, SR Downing, ... Clinical cancer research 19 (10), 2668-2676, 2013 | 154 | 2013 |
